MPNs

In an interview with Targeted Oncology, Joseph M. Scandura, MD, PhD, discussed research on pelabresib for the treatment of patients with myeloproliferative neoplasms.

Findings from a 5-patient study evaluating azacitidine, venetoclax, and ruxolitinib for the treatment of myeloproliferative neoplasms shows promise. More research is warranted.

During a Targeted Oncology™ Case-Based Roundtable™ event, Abdulraheem Yacoub, MD, and participants discussed the process of initiating JAK inhibitor therapy for a patient with primary myelofibrosis.

In a phase 1b trial, AVID200 demonstrated limited toxicity and improved symptom benefit when administered at 3 doses levels.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, discussed the development of Janus kinase inhibitors and how newer therapies meet needs of patients with cytopenic myelofibrosis.

The FDA has granted fast track designation to MWTX-003 for the treatment of patients with polycythemia vera.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.

Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.

Momelotinib has emerged as a new FDA-approved treatment option for patients with myelofibrosis and anemia.

According to Ruben A. Mesa, MD, FACP, confirming the benefit of long-acting interferon for essential thrombocytopenia is key.

With multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis.

At the SOHO 2023 Annual Meeting, Mohammad Bakri Hammami, MD, spoke about the need to address disparities related to race, sex, and age among patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed elements to diagnosing myelofibrosis and how to approach risk stratification before treatment.

The therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, and participants discussed the role of JAK inhibitors in managing myelofibrosis particularly in younger patients who may receive allogeneic stem cell transplant. This is the first of 2 articles based on this event.

During a Targeted Oncology™ Case-Based Roundtable™ event, Gabriela S. Hobbs, MD, reviewed the data for frontline use of JAK inhibitors to treat patients with primary myelofibrosis.

Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial and where momelotinib goes from here in the treatment of patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

Phase 3 research is underway to explore the efficacy and safety of selinexor plus ruxolitinib for the treatment of myelofibrosis in adults.

In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.

Joseph M. Scandura, MD, PhD, discusses research regarding pelabresib for patients with myeloproliferative neoplasms.

Following promising phase 1 study results, the combination of selinexor and ruxolitinib is being evaluated in a phase 3 trial in patients with myelofibrosis.

After positive results from the phase 1/2 KRT-232-109 study, the phase 3 BOREAS-2 study will further evaluate the combination of navtemadlin and ruxolitinib in patients with myelofibrosis.

Post-hoc analysis results showed a reduction in spleen volume of 35% with ruxolitinib in patients with myelofibrosis.

Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

Results from the phase 2 MAJIC-PV study showed that patients with polycythemia vera who are intolerant to hydroxycarbamide chemotherapy had superior efficacy results on ruxolitinib.